课题基金 / 基金详情

Dynamical Models of Cetuximab Resistance in HNSCC Based on Serial Genomics Data

Dynamical Models of Cetuximab Resistance in HNSCC Based on Serial Genomics Data
基于系列基因组数据的 HNSCC 西妥昔单抗耐药动态模型
批准号:
9325461
负责人:
Elana Judith Fertig
金额:
$33.62万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-16 至 2019-08-31

项目摘要

项目成果

Elana Judith Fertig的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Head and neck squamous cell carcinoma (HNSCC) is the sixth most frequent cancer worldwide, with only a 50% cure rate in spite of combined treatment modalities. Therapeutic targeting of the epidermal growth factor receptor (EGFR) improves the survival in a subset of patients, although molecular predictors of sensitivity are currently elusive. Moreover, responsive patients often acquire resistance and ultimately succumb to their disease. Distinguishing the specific molecular processes that drive such therapeutic resistance amid complex cross-talk in cell signaling processes and stochastic evolutionary pressures requires dynamical models built from serial data. Therefore, in this application, we develop novel computational algorithms to infer the molecular mechanisms underlying cetuximab resistance from in vitro and in vivo model of cetuximab resistant HNSCC. Specifically, we will investigate the hypotheses that: (1) short-term time course data improve the ability of in silicon modeling techniques to infer both on- and off-target signaling responses to cetuximab; (2) combined epigenetic, post-transcriptional, and genomic changes in HNSCC cells upon chronic exposure to cetuximab result in acquired resistance; and (3) modeling inter and intra-individual heterogeneity will discern the specific cellular signaling processes that are activated to drive in vivo acquired cetuximab resistance in cell- line xenograft models of HNSCC. The results from this project will ultimately contribute to the selection of patients for cetuximab treatment and alternative molecular targets to overcome acquired cetuximab resistance. The algorithms developed will also be directly applicable to inference of molecular drivers of therapeutic resistance in additional cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multiscale Computational Oncology Research Core
Data Analysis Core
  • 批准号:
    10556891
  • 项目类别:
  • 资助金额:
    $21.62万
  • 财政年份:
    2022
  • 负责人:
    Elana Judith Fertig
  • 依托单位:
Data Analysis Core
  • 批准号:
    10673121
  • 项目类别:
  • 资助金额:
    $22.09万
  • 财政年份:
    2022
  • 负责人:
    Elana Judith Fertig
  • 依托单位:
Interrogation of the Impact of Selection on the Evolution of Human Pancreatic Cancer Precursor Lesions
  • 批准号:
    10703414
  • 项目类别:
  • 资助金额:
    $53.11万
  • 财政年份:
    2022
  • 负责人:
    Elana Judith Fertig
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: